Security Snapshot

Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) Institutional Ownership

CUSIP: 48576U106

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

0

Shares (Excl. Options)

0

Price

$0.60

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
KPTI on Nasdaq
Shares outstanding
22,242,217
Price per share
$0.60
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
0
Total reported value
$0
Share change
-27,985
Value change
-$183,022
Number of holders
0
Price from insider filings
$0.60
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 48576U106.
  • 0 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
  • Reported value moved from $183,022 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 0 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 48576U106?
CUSIP 48576U106 identifies KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Adage Capital Management, L.P. 5.2% $24,500,946 6,551,055 Adage Capital Management, L.P. 31 Dec 2024
RA CAPITAL MANAGEMENT, L.P. 9.9% $1,247,348 2,078,913 RA Capital Management, L.P. 26 Mar 2026
Commodore Capital LP 9.9% $1,170,000 1,950,000 Commodore Capital LP 26 Mar 2026
INTEGRATED CORE STRATEGIES (US) LLC 2.3% $306,943 511,571 Millennium Management LLC 31 Mar 2026

As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI). This represents 0% of the company’s total 22,242,217 outstanding shares.

Institutional Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$183,022 $0.60 0
2025 Q3 27,985 $183,022 $6.54 1
2025 Q2 27,985 $120,615 -$1,211,880 $4.31 1
2025 Q1 352,017 $1,316,544 -$55,318,808 $3.74 2
2024 Q4 60,912,948 $41,204,113 -$289,373 $0.68 87
2024 Q3 59,278,240 $49,194,051 -$6,331,563 $0.83 90
2024 Q2 67,556,361 $58,626,062 -$7,639,125 $0.87 114
2024 Q1 74,702,822 $112,801,347 +$3,989,777 $1.51 111
2023 Q4 73,344,053 $63,441,322 -$4,574,345 $0.86 118
2023 Q3 76,219,647 $102,134,785 -$10,719,386 $1.34 117
2023 Q2 80,450,419 $144,011,333 -$18,617,679 $1.79 133
2023 Q1 87,557,859 $340,123,767 -$32,799,976 $3.89 128
2022 Q4 98,414,676 $334,456,268 +$99,576,581 $3.40 152
2022 Q3 66,862,684 $365,052,989 -$620,374 $5.46 142
2022 Q2 67,139,765 $302,788,902 -$7,006,335 $4.51 144
2022 Q1 68,286,528 $501,776,522 +$108,241,216 $7.37 134
2021 Q4 54,170,305 $347,414,468 -$3,383,122 $6.43 138
2021 Q3 57,408,855 $334,396,841 -$25,823,482 $5.82 130
2021 Q2 58,982,285 $608,669,781 -$13,934,484 $10.32 147
2021 Q1 59,160,795 $622,242,344 -$49,072,460 $10.52 163
2020 Q4 63,829,194 $988,058,899 -$54,468,075 $15.48 165
2020 Q3 65,150,667 $951,174,601 -$110,130,293 $14.60 155
2020 Q2 69,738,739 $1,320,807,090 +$45,201,421 $18.94 155
2020 Q1 67,992,711 $1,305,743,291 +$217,084,502 $19.21 135
2019 Q4 58,955,103 $1,130,098,649 -$54,693,103 $19.17 146
2019 Q3 58,481,490 $562,607,545 +$83,519,427 $9.62 105
2019 Q2 51,164,991 $306,457,439 +$3,407,218 $5.99 102
2019 Q1 51,219,533 $299,625,643 -$24,705,356 $5.84 101
2018 Q4 51,412,770 $481,695,108 +$75,184,187 $9.37 116
2018 Q3 43,286,107 $737,162,850 -$818,029 $17.03 117
2018 Q2 43,354,403 $736,589,579 +$217,013,290 $16.99 108
2018 Q1 30,891,981 $414,567,351 +$174,090 $13.42 87
2017 Q4 31,007,107 $297,662,901 +$20,343,235 $9.60 88
2017 Q3 28,741,389 $315,542,785 +$10,686,137 $10.98 74
2017 Q2 27,780,067 $251,407,245 +$6,202,394 $9.05 71
2017 Q1 26,846,913 $344,713,183 +$45,322,035 $12.84 79
2016 Q4 25,467,293 $239,390,343 +$21,237,489 $9.40 85
2016 Q3 23,180,959 $225,551,522 +$31,499,955 $9.73 77
2016 Q2 20,044,622 $134,499,864 -$8,387,552 $6.71 73
2016 Q1 21,165,907 $188,770,460 -$5,334,988 $8.92 76
2015 Q4 21,560,134 $285,674,019 -$24,016,754 $13.25 86
2015 Q3 23,545,780 $247,934,145 -$6,616,775 $10.53 87
2015 Q2 22,391,611 $609,266,884 +$40,371,623 $27.21 88
2015 Q1 20,794,207 $636,290,225 +$53,545,677 $30.61 85
2014 Q4 18,742,387 $701,526,058 +$50,285,065 $37.43 81
2014 Q3 16,817,880 $587,612,971 +$52,881,540 $34.94 70
2014 Q2 15,117,534 $703,718,591 +$235,116,570 $46.55 78
2014 Q1 10,072,951 $310,923,978 +$33,552,565 $30.89 59